Verona Pharma (NASDAQ: VRNA) jumped over 20% after Merck (NYSE: MRK) announced it was buying the company for $10 billion, or ...

Fintel reports that on July 10, 2025, Wells Fargo downgraded their outlook for Verona Pharma plc - Depositary Receipt () ...

Merck’s recent acquisition announcement sends a strong signal regarding its urgency to tackle the impending Keytruda patent ...

This acquisition of Verona Pharma reflects the commitment we have to delivering innovative treatments to patients and our ...

Merck & Co. Inc. (NYSE:MRK) is one of the most undervalued NYSE stocks to buy now. On July 9, Merck announced its acquisition ...

Verona Pharma brings to Merck the inhaled drug Ohtuvayre, which is FDA approved as a treatment for chronic obstructive ...

Merck says it will acquire London-based Verona Pharma for about US$10bil, gaining a promising respiratory treatment as it ...

A key patent for Merck’s blockbuster drug Keytruda will expire in 2028. The cancer therapy brought the company $29.5 billion last year. Keytruda may also face “ price setting ” from the Inflation ...

Amarna Therapeutics and NorthX Biologics finalized an agreement to advance Nimvec AM510 gene therapy toward clinical trials for Type 1 Diabetes. Now in its fourth year, the MM+M Media Summit brings ...

This is an audio transcript of the FT News Briefing podcast episode: ‘Big Pharma markets left in a ‘patent cliff’-hanger’ ...

When blockbuster drugs lose intellectual property protections it can wipe out billions of dollars in revenue for companies ...

The effort appears to be paying off – last year Johnson & Johnson turned to Freshfields over its usual choice Cravath for its $13bn acquisition of medical device maker Shockwave Medical, with the team ...